Novavax raises doubts about its ability to remain in business https://ift.tt/RyBPqUN

The company said there is significant uncertainty around its 2023 revenue, funding from the U.S. government, and pending arbitration with global vaccine alliance GAVI. But its cash flow forecast indicates it has sufficient capital to fund operations over the next year.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/FwDvqCK